Association between the loudness dependence of auditory evoked potential, serotonergic neurotransmission and treatment outcome in patients with depression
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Association between the loudness dependence of auditory evoked potential, serotonergic neurotransmission and treatment outcome in patients with depression. / Ip, Cheng-Teng; Ganz, Melanie; Ozenne, Brice; Olbrich, Sebastian; Beliveau, Vincent; Dam, Vibeke H; Köhler-Forsberg, Kristin; Jørgensen, Martin B.; Frøkjær, Vibe G; Knudsen, Gitte M.
In: European Neuropsychopharmacology, Vol. 70, 2023, p. 32-44.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Association between the loudness dependence of auditory evoked potential, serotonergic neurotransmission and treatment outcome in patients with depression
AU - Ip, Cheng-Teng
AU - Ganz, Melanie
AU - Ozenne, Brice
AU - Olbrich, Sebastian
AU - Beliveau, Vincent
AU - Dam, Vibeke H
AU - Köhler-Forsberg, Kristin
AU - Jørgensen, Martin B.
AU - Frøkjær, Vibe G
AU - Knudsen, Gitte M
N1 - Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Previous studies have suggested that the loudness dependence of auditory evoked potential (LDAEP) is associated with the effectiveness of antidepressant treatment in patients with major depressive disorders (MDD). Furthermore, both LDAEP and the cerebral serotonin 4 receptor (5-HT 4R) density is inversely related to brain serotonin levels. We included 84 patients with MDD and 22 healthy controls to examined the association between LDAEP and treatment response and its association with cerebral 5-HT 4R density. Participants underwent both EEG and 5-HT 4R neuroimaging with [ 11C]SB207145 PET. Thirty-nine patients with MDD were re-examined after 8 weeks of treatment with selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitor (SSRI/SNRI). We found that the cortical source of LDAEP was higher in untreated patients with MDD compared to healthy controls (p=0.03). Prior to SSRI/SNRI treatment, subsequent treatment responders had a negative association between LDAEP and depressive symptoms and a positive association between scalp LDAEP and symptom improvement at week 8. This was not found in source LDAEP. In healthy controls, we found a positive correlation between both scalp and source LDAEP and cerebral 5-HT 4R binding but that was not observed in patients with MDD. We did not see any changes in scalp and source LDAEP in response to SSRI/SNRI treatment. These results support a theoretical framework where both LDAEP and cerebral 5-HT 4R are indices of cerebral 5-HT levels in healthy individuals while this association seems to be disrupted in MDD. The combination of the two biomarkers may be useful for stratifying patients with MDD. Clinical Trials Registration:https://clinicaltrials.gov/ct2/show/NCT02869035?draw=1Registration number: NCT0286903.
AB - Previous studies have suggested that the loudness dependence of auditory evoked potential (LDAEP) is associated with the effectiveness of antidepressant treatment in patients with major depressive disorders (MDD). Furthermore, both LDAEP and the cerebral serotonin 4 receptor (5-HT 4R) density is inversely related to brain serotonin levels. We included 84 patients with MDD and 22 healthy controls to examined the association between LDAEP and treatment response and its association with cerebral 5-HT 4R density. Participants underwent both EEG and 5-HT 4R neuroimaging with [ 11C]SB207145 PET. Thirty-nine patients with MDD were re-examined after 8 weeks of treatment with selective serotonin reuptake inhibitors/serotonin noradrenaline reuptake inhibitor (SSRI/SNRI). We found that the cortical source of LDAEP was higher in untreated patients with MDD compared to healthy controls (p=0.03). Prior to SSRI/SNRI treatment, subsequent treatment responders had a negative association between LDAEP and depressive symptoms and a positive association between scalp LDAEP and symptom improvement at week 8. This was not found in source LDAEP. In healthy controls, we found a positive correlation between both scalp and source LDAEP and cerebral 5-HT 4R binding but that was not observed in patients with MDD. We did not see any changes in scalp and source LDAEP in response to SSRI/SNRI treatment. These results support a theoretical framework where both LDAEP and cerebral 5-HT 4R are indices of cerebral 5-HT levels in healthy individuals while this association seems to be disrupted in MDD. The combination of the two biomarkers may be useful for stratifying patients with MDD. Clinical Trials Registration:https://clinicaltrials.gov/ct2/show/NCT02869035?draw=1Registration number: NCT0286903.
U2 - 10.1016/j.euroneuro.2023.02.008
DO - 10.1016/j.euroneuro.2023.02.008
M3 - Journal article
C2 - 36863106
VL - 70
SP - 32
EP - 44
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
ER -
ID: 338727365